Cargando…

A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease

INTRODUCTION: Total kidney volume (TKV) is a promising imaging biomarker for tracking and predicting the natural history of patients with autosomal dominant polycystic kidney disease. METHODS: A drug development tool was developed by linking longitudinal TKV measurements to the probability of a 30%...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perrone, Ronald D., Mouksassi, Mohamad-Samer, Romero, Klaus, Czerwiec, Frank S., Chapman, Arlene B., Gitomer, Berenice Y., Torres, Vicente E., Miskulin, Dana C., Broadbent, Steve, Marier, Jean F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678607/ https://www.ncbi.nlm.nih.gov/pubmed/29142972 http://dx.doi.org/10.1016/j.ekir.2017.02.011

Ejemplares similares

Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease
por: Perrone, Ronald D., et al.
Publicado: (2017)

Pain and Obesity in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis of the Halt Progression of Polycystic Kidney Disease (HALT-PKD) Studies
por: Nowak, Kristen L., et al.
Publicado: (2021)

Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial
por: Irazabal, Maria V., et al.
Publicado: (2016)

Erythropoietin and Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease Patients
por: Hanudel, Mark R., et al.
Publicado: (2019)

Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease
por: Grantham, Jared J., et al.
Publicado: (2017)

Developments in the management of autosomal dominant polycystic kidney disease
por: Masoumi, Amirali, et al.
Publicado: (2008)

Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial
por: Shoaf, Susan E., et al.
Publicado: (2017)

Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial
por: Casteleijn, Niek F., et al.
Publicado: (2016)

Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease
por: Dad, Taimur, et al.
Publicado: (2018)

Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial
por: Torres, Vicente E, et al.
Publicado: (2018)

Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial
por: Cornec-Le Gall, Emilie, et al.
Publicado: (2018)

Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4
por: Devuyst, Olivier, et al.
Publicado: (2017)

Affected parent sex and severity of autosomal dominant polycystic kidney disease: a retrospective cohort study
por: Nowak, Kristen L., et al.
Publicado: (2018)

Metabolic profiling in children and young adults with autosomal dominant polycystic kidney disease
por: Baliga, Madhurima M., et al.
Publicado: (2021)

Prevalence of autosomal dominant polycystic kidney disease in the European Union
por: Willey, Cynthia J., et al.
Publicado: (2017)

Standardizing total kidney volume measurements for clinical trials of autosomal dominant polycystic kidney disease
por: Edwards, Marie E, et al.
Publicado: (2018)

Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data
por: Knight, Tyler, et al.
Publicado: (2015)

CD8(+) T cells modulate autosomal dominant polycystic kidney disease progression
por: Kleczko, Emily K., et al.
Publicado: (2018)

Evaluation of covariate effects using forest plots and introduction to the coveffectsplot R package
por: Marier, Jean‐Francois, et al.
Publicado: (2022)

Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease
por: Hopp, Katharina, et al.
Publicado: (2021)

Autosomal dominant polycystic kidney
por: Gudadhe, Rugaved Raghavendra, et al.
Publicado: (2022)

Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?
por: Brosnahan, Godela M., et al.
Publicado: (2018)

Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease
por: Steinman, Theodore
Publicado: (2016)

Curcumin therapy to treat vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease: Design and baseline characteristics of participants
por: Nowak, Kristen L., et al.
Publicado: (2020)

Total Kidney Volume as a Biomarker of Disease Progression in Autosomal Dominant Polycystic Kidney Disease
por: Tangri, Navdeep, et al.
Publicado: (2017)

Patient-reported outcome measures for pain in autosomal dominant polycystic kidney disease: A systematic review
por: Natale, Patrizia, et al.
Publicado: (2021)

Prognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease
por: El Ters, Mireille, et al.
Publicado: (2021)

Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database
por: Watkins, Paul B., et al.
Publicado: (2015)

Autosomal dominant polycystic kidney disease in Colombia
por: Camargo, Jessica T., et al.
Publicado: (2023)

Urinary Proteomic Biomarkers for Diagnosis and Risk Stratification of Autosomal Dominant Polycystic Kidney Disease: A Multicentric Study
por: Kistler, Andreas D., et al.
Publicado: (2013)

Epidemiology of autosomal-dominant polycystic liver disease in Olmsted county
por: Suwabe, Tatsuya, et al.
Publicado: (2020)

Bacterial Cholangitis in Autosomal Dominant Polycystic Kidney and Liver Disease
por: Martin, William P., et al.
Publicado: (2019)

Correction: Urinary Proteomic Biomarkers for Diagnosis and Risk Stratification of Autosomal Dominant Polycystic Kidney Disease: A Multicentric Study
por: Kistler, Andreas D., et al.
Publicado: (2013)

Hypertension in autosomal-dominant polycystic kidney disease (ADPKD)
por: Sans-Atxer, Laia, et al.
Publicado: (2013)

Nephrotic syndrome and autosomal dominant polycystic kidney disease
por: Visciano, Bianca, et al.
Publicado: (2012)

Umbilical hernia in autosomal dominant polycystic kidney disease
por: Hattori, Yoshinari, et al.
Publicado: (2014)

Diagnostic Imaging of Autosomal Dominant Polycystic Kidney Disease
por: Gradzik, Monika, et al.
Publicado: (2016)

Obturator hernia in autosomal dominant polycystic kidney disease
por: Jung, Jong Hwan, et al.
Publicado: (2018)

Autosomal dominant polycystic kidney disease: updated perspectives
por: Rastogi, Anjay, et al.
Publicado: (2019)

Educational Case: Autosomal Dominant Polycystic Kidney Disease
por: Frazier, Ryan L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cngq293dkp1gunq352chfqcftp